AI 聊天
Loading data for IMNN — first visit, this takes a few seconds.

Imunon, Inc.

IMNN · NasdaqCM · USD

1.47 +0.02 (1.38%)

收盤價: Sep 18, 2026, 8:00 PM

1.45 +6.62%

盤後: 7:30 PM

市值
$7.63M

Imunon, Inc.(IMNN)股價、分析與資料

內在價值

估值模型屬於 Pro 功能。登入或升級後可查看完整分析。

查看方案 →

分析師預測

股票預測 →

分析師預測無法取得

12個月目標價 · n/a 位分析師

分析師共識: n/a

間隔:1D
正在載入K線和訊號…

財務表現

查看財務 →

正在載入...

最新財報

已通報較預期YoY 變更
營收n/an/a
EPS-$0.54+$0.37+71.12%

下次財報

查看財報詳情 →

指標

買價
1.09
市值
7.63M
淨利(ttm)
-14.7M
1.98
-2.92
n/a
-0.77
P/B (ttm)
3.28
P/S (ttm)
n/a
財報日期
n/a
賣價
1.85
成交量
129,159
20 日平均成交量
141,240
開盤價
1.45
前收盤價
1.45
當日區間
1.42 - 1.53
52 週範圍
1.39 - 5.85
股利
n/a
除息日
n/a

關於 Imunon, Inc.

查看公司資料 →
Imunon, Inc., a clinical-stage biotechnology company, focuses on developing immunotherapies and vaccines in the United States. The company's lead clinical program is IMNN-001, a DNA-based immunotherapy that is in a Phase 3 clinical trial for the localized treatment of advanced ovarian cancer, as well as in the IND-enabling phase for colorectal and pancreatic cancers, and in the discovery phase for glioblastoma. It is also developing IMNN-101, a COVID-19 booster vaccine that has completed a Phase 1 clinical trial. In addition, the company develops non-viral DNA technology across modalities, such as TheraPlas for the coding of proteins and cytokines in the treatment of solid tumors; and PlaCCine for the coding of viral antigens that can elicit a strong immunological response. The company was formerly known as Celsion Corporation and changed its name to Imunon, Inc. in September 2022. Imunon, Inc. was incorporated in 1982 and is headquartered in Lawrenceville, New Jersey. Biotechnology · Healthcare

Imunon, Inc., a clinical-stage biotechnology company, focuses on developing immunotherapies and vaccines in the United States. The company's lead clinical program is IMNN-001, a DNA-based immunotherapy that is in a Phase 3 clinical trial for the localized treatment of advanced ovarian cancer, as well as in the IND-enabling phase for colorectal and pancreatic cancers, and in the discovery phase for glioblastoma. It is also developing IMNN-101, a COVID-19 booster vaccine that has completed a Phase 1 clinical trial. In addition, the company develops non-viral DNA technology across modalities, such as TheraPlas for the coding of proteins and cytokines in the treatment of solid tumors; and PlaCCine for the coding of viral antigens that can elicit a strong immunological response. The company was formerly known as Celsion Corporation and changed its name to Imunon, Inc. in September 2022. Imunon, Inc. was incorporated in 1982 and is headquartered in Lawrenceville, New Jersey.

類股 Healthcare
IPO 日期 Mar 1, 1999
員工 20
證券交易所 NasdaqCM
股票代號 IMNN